TY - JOUR
T1 - Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy
AU - Mocroft, Amanda
AU - Phillips, Andrew N
AU - Ledergerber, Bruno
AU - Smith, Colette
AU - Bogner, Johannes R
AU - Lacombe, Karine
AU - Wiercinska-Drapalo, Alicje
AU - Reiss, Peter
AU - Kirk, Ole
AU - Lundgren, Jens
AU - Eurosida Study Group
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Background: Patients receiving combination antiretroviral therapy (cART) might continue treatment with a virologically failing regimen. We sought to identify annual change in CD4+ T-cell count according to levels of viraemia in patients on cART. Methods: A total of 111,371 CD4+ T-cell counts and viral load measurements in 8,227 patients were analysed. Annual change in CD4+ T-cell numbers was estimated using mixed models. Results: After adjustment, the estimated average annual change in CD4 + T-cell count significantly increased when viral load was <500 copies/ml (30.4 cells/mm3, 95% confidence interval [CI] 26.6-34.3), was stable when viral load was 500-9,999 copies/ml (3.1 cells/mm3, 95% CI -5.3-11.5) and decreased when viral load was ≥10,000 copies/ml (-14.8 cells/mm3, 95% CI -4.5- - 25.1). Patients taking a boosted protease inhibitor (PI) regimen had more positive annual CD4+ T-cell count changes than patients taking other regimens for any given viral load strata: 30.9 cells/mm3 (95% CI 27.7-34.1) when viral load was <500 copies/ml, 14.2 cells/mm3 (95% CI -2.1-30.4) when viral load was 500-9,999 copies/ml and -19.9 cells/mm3 (95% CI -36.6- -3.3) when viral load was ≥10,000 copies/ml. By contrast, among patients taking a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, the CD4+ T-cell count significantly decreased when the viral load was 500-9,999 copies/ml (-18.6 cells/mm3, 95% CI -33.8- - 3.5) and decreased at a faster rate when the viral load was ≥10,000 copies/ml (-44.4 cells/mm3, 95% CI -62.0- -26.9; P=0.0012, test for interaction). Conclusions: On average, CD4+ T-cell counts did not significantly decrease until the viral load exceeded 10,000 copies/ml in patients treated with a boosted PI-containing cART regimen, but decreased in patients taking an NNRTI-based cART regimen when viral load was 500-9,999 copies/ml.
AB - Background: Patients receiving combination antiretroviral therapy (cART) might continue treatment with a virologically failing regimen. We sought to identify annual change in CD4+ T-cell count according to levels of viraemia in patients on cART. Methods: A total of 111,371 CD4+ T-cell counts and viral load measurements in 8,227 patients were analysed. Annual change in CD4+ T-cell numbers was estimated using mixed models. Results: After adjustment, the estimated average annual change in CD4 + T-cell count significantly increased when viral load was <500 copies/ml (30.4 cells/mm3, 95% confidence interval [CI] 26.6-34.3), was stable when viral load was 500-9,999 copies/ml (3.1 cells/mm3, 95% CI -5.3-11.5) and decreased when viral load was ≥10,000 copies/ml (-14.8 cells/mm3, 95% CI -4.5- - 25.1). Patients taking a boosted protease inhibitor (PI) regimen had more positive annual CD4+ T-cell count changes than patients taking other regimens for any given viral load strata: 30.9 cells/mm3 (95% CI 27.7-34.1) when viral load was <500 copies/ml, 14.2 cells/mm3 (95% CI -2.1-30.4) when viral load was 500-9,999 copies/ml and -19.9 cells/mm3 (95% CI -36.6- -3.3) when viral load was ≥10,000 copies/ml. By contrast, among patients taking a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, the CD4+ T-cell count significantly decreased when the viral load was 500-9,999 copies/ml (-18.6 cells/mm3, 95% CI -33.8- - 3.5) and decreased at a faster rate when the viral load was ≥10,000 copies/ml (-44.4 cells/mm3, 95% CI -62.0- -26.9; P=0.0012, test for interaction). Conclusions: On average, CD4+ T-cell counts did not significantly decrease until the viral load exceeded 10,000 copies/ml in patients treated with a boosted PI-containing cART regimen, but decreased in patients taking an NNRTI-based cART regimen when viral load was 500-9,999 copies/ml.
U2 - 10.3851/imp1559
DO - 10.3851/imp1559
M3 - Journal article
C2 - 20587849
SN - 1359-6535
VL - 15
SP - 563
EP - 570
JO - Antiviral Therapy
JF - Antiviral Therapy
IS - 4
ER -